CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $2.02 billion. The enterprise value is $1.36 billion.
Important Dates
The last earnings date was Friday, August 8, 2025, before market open.
Earnings Date | Aug 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 76.25 million shares outstanding. The number of shares has increased by 376.91% in one year.
Current Share Class | 76.25M |
Shares Outstanding | 76.25M |
Shares Change (YoY) | +376.91% |
Shares Change (QoQ) | +0.05% |
Owned by Insiders (%) | 0.68% |
Owned by Institutions (%) | 94.27% |
Float | 61.15M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3,665.70 |
Forward PS | n/a |
PB Ratio | 3.01 |
P/TBV Ratio | 3.01 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 2,467.77 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.15, with a Debt / Equity ratio of 0.00.
Current Ratio | 22.15 |
Quick Ratio | 21.78 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -23.44% |
Revenue Per Employee | $4,876 |
Profits Per Employee | -$1.13M |
Employee Count | 113 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -19.48% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -19.48% |
50-Day Moving Average | 26.21 |
200-Day Moving Average | 27.84 |
Relative Strength Index (RSI) | 53.21 |
Average Volume (20 Days) | 965,715 |
Short Selling Information
The latest short interest is 11.00 million, so 14.43% of the outstanding shares have been sold short.
Short Interest | 11.00M |
Short Previous Month | 10.78M |
Short % of Shares Out | 14.43% |
Short % of Float | 18.00% |
Short Ratio (days to cover) | 11.27 |
Income Statement
In the last 12 months, CG Oncology had revenue of $551,000 and -$128.08 million in losses. Loss per share was -$1.77.
Revenue | 551,000 |
Gross Profit | -84.18M |
Operating Income | -157.29M |
Pretax Income | n/a |
Net Income | -128.08M |
EBITDA | -157.09M |
EBIT | -157.29M |
Loss Per Share | -$1.77 |
Full Income Statement Balance Sheet
The company has $661.05 million in cash and $994,000 in debt, giving a net cash position of $660.06 million or $8.66 per share.
Cash & Cash Equivalents | 661.05M |
Total Debt | 994,000 |
Net Cash | 660.06M |
Net Cash Per Share | $8.66 |
Equity (Book Value) | 670.36M |
Book Value Per Share | 8.79 |
Working Capital | 642.65M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$93.82 million and capital expenditures -$238,000, giving a free cash flow of -$94.06 million.
Operating Cash Flow | -93.82M |
Capital Expenditures | -238,000 |
Free Cash Flow | -94.06M |
FCF Per Share | -$1.23 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | -28,546.10% |
Pretax Margin | -23,245.19% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -376.91% |
Shareholder Yield | -376.91% |
Earnings Yield | -6.34% |
FCF Yield | -4.66% |
Analyst Forecast
The average price target for CG Oncology is $63.30, which is 138.96% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $63.30 |
Price Target Difference | 138.96% |
Analyst Consensus | Strong Buy |
Analyst Count | 11 |
Revenue Growth Forecast (5Y) | 271.50% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
CG Oncology has an Altman Z-Score of 41.68 and a Piotroski F-Score of 1.
Altman Z-Score | 41.68 |
Piotroski F-Score | 1 |